760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Yoshinobu Koguchi; Noriko Iwamoto; Takashi Shimada; Shu-Ching Chang; John Cha; Brian D. Piening; Brendan Curti; Walter Urba; William L Redmond

doi:10.1136/JITC-2020-SITC2020.0760

760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brian D. Piening, Brendan Curti, Walter Urba, William L Redmond

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal for ImmunoTherapy of Cancer
Volume	8
DOIs	https://doi.org/10.1136/JITC-2020-SITC2020.0760
State	Published - Nov 1 2020

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1136/JITC-2020-SITC2020.0760License: Unspecified

Cite this

Koguchi, Y., Iwamoto, N., Shimada, T., Chang, S.-C., Cha, J., Piening, B. D., Curti, B., Urba, W., & Redmond, W. L. (2020). 760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. Journal for ImmunoTherapy of Cancer, 8. https://doi.org/10.1136/JITC-2020-SITC2020.0760

@article{e03dd405e0d9457fbf456121e654f934,

title = "760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab",

author = "Yoshinobu Koguchi and Noriko Iwamoto and Takashi Shimada and Shu-Ching Chang and John Cha and Piening, {Brian D.} and Brendan Curti and Walter Urba and Redmond, {William L}",

year = "2020",

month = nov,

day = "1",

doi = "10.1136/JITC-2020-SITC2020.0760",

language = "American English",

volume = "8",

journal = "Journal for ImmunoTherapy of Cancer",

}

TY - JOUR

T1 - 760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

AU - Koguchi, Yoshinobu

AU - Iwamoto, Noriko

AU - Shimada, Takashi

AU - Chang, Shu-Ching

AU - Cha, John

AU - Piening, Brian D.

AU - Curti, Brendan

AU - Urba, Walter

AU - Redmond, William L

PY - 2020/11/1

Y1 - 2020/11/1

UR - https://jitc.bmj.com/content/jitc/8/Suppl_3/A455.2.full.pdf

U2 - 10.1136/JITC-2020-SITC2020.0760

DO - 10.1136/JITC-2020-SITC2020.0760

M3 - Article

VL - 8

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

ER -

760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Disciplines

Access to Document

Other files and links

Cite this